🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against superbug strains of the pathogen, according to scientists.

A Worldwide Challenge

The sexually transmitted infection are escalating around the world, with estimates suggesting in excess of 82 million new cases each year. Especially elevated rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary advancement in the context of growing infection rates, escalating drug resistance and the highly restricted therapeutic options presently on offer.”

Health officials are deeply concerned about the surge in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Authorization

One new antibiotic, alternatively called a brand name, was cleared by the US FDA in mid-December for combating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists anticipate that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to see it through.

“This milestone marks a significant shift in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Results and Worldwide Availability

As per results detailed in a prominent scientific publication, the new drug eradicated the vast majority of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which uses a dual-drug approach. The study involved nearly 1,000 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the rights to register and commercialise the drug in many developing nations.

Doctors on the front lines have voiced hope. The availability of a single-dose, oral treatment such as this is described as a "critical tool" for public health efforts. This is considered essential to reduce the burden of the illness for people and to halt the transmission of extremely resistant gonorrhoea worldwide.